• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Zoetis (ZTS) Cuts Its Revenue Outlook, Is The Stock Cheap?

    Simply Wall St·11/10/2026 04:41:59
    Listen to the news

    Earnings setback and updated outlook put Zoetis in focus

    Zoetis (ZTS) stepped into the spotlight after reporting third quarter 2026 results that showed slightly lower revenue and profit, paired with a narrowed full year outlook and refreshed earnings guidance.

    The latest earnings miss arrived after a rough stretch for shareholders, with the share price down 34.63% year to date and the 5 year total shareholder return falling 59.47%. However, a 10.04% 1 month share price gain hints at stabilising sentiment around Zoetis.

    Compare Zoetis with a curated group of animal health and pharmaceutical peers that currently screen as 33 high quality undervalued stocks on Simply Wall St.

    The share price slump, the recent rebound and a fair value range that sits well above or below US$82 all tell different stories. Where does Zoetis actually line up against those estimates?

    Most Popular Narrative: 11% Undervalued

    Against the last close at $82.32, the leading Zoetis narrative pegs fair value at $92.92, which points to an 11.4% discount and frames the recent price slump as a valuation gap rather than a permanent reset according to ValueInvestingSubstack, an investor in the Simply Wall St Community who authored the narrative.

    On one hand it’s not a business that’s going to grow much. On the other hand, it’s also not likely to collapse catastrophically. Double-edged sword. The company cites generics as a potential risk in its financial statements. I’m not sure how much of this could be attributable to the 11% YoY decline in Pet segment revenues, but this is just something to watch out for if you’re interested in investing in the business.

    See why 28 investors see Zoetis as 11% undervalued.

    The fair value in that work is based on a discount rate of 7.11%, which reflects how the author weighs Zoetis cash flows against risk. With earnings forecast to grow 4.5% per year and revenue projected to rise 2.1% annually, the story leans more on durability of profits and cash generation than on rapid expansion.

    That tilt matters when you line it up against the SWS discounted cash flow output. The internal statements suggest Zoetis trades 57.5% below an estimate of its future cash flow value of $193.92 per share. The narrative fair value of $92.92 sits between that long runway and today’s market price, which gives readers a reference point if they prefer a more conservative anchor than the full DCF result.

    On top of that, the stock scores as good value across several checks against peers in the US pharmaceuticals sector, and against an estimated fair P/E ratio of 23.2x. The current P/E of 13.3x is below both that fair ratio and the 15.2x industry average, which lines up with the idea that the market price is not fully reflecting the firm’s profitability, high quality earnings and forecast return on equity of 51.9% in three years time, even after factoring in its higher leverage.

    Result: Fair Value of $92.92 (UNDERVALUED)

    Still, the Zoetis thesis leans heavily on the Companion Animal segment stabilising and on debt funded buybacks not stretching the balance sheet further if conditions change.

    Find out about the key risks to this Zoetis narrative.

    Next Steps

    Mixed signals are everywhere in the Zoetis story right now, so move quickly, study the underlying numbers, and judge the trade off for yourself with 4 key rewards and 1 important warning sign.

    Looking for more Zoetis investment ideas?

    If Zoetis has your attention, do not stop here. Broader context from other opportunities can sharpen your judgement and help you spot mispriced potential.